Pandemic
Iomai Announces First Quarter 2007 Financial Results and Business Progress
Published in TB and Outbreaks Week, May 29th, 2007
"This has been a productive quarter for us, highlighted by the government's decision to award Iomai a $128 million contract for the development of a dose-sparing booster patch that can be used to cut the amount of influenza vaccine required for protection in the event of a flu pandemic. We have already achieved the first milestone under that contract, which was the submission of a product development plan, on time," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "We further validated our core technology -- transcutaneous...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Epidemic
Book Explores History, Causes of Allergy and Asthma Epidemic - West Nile Virus
UT Southwestern joins national clinical trial that seeks to uncover long-term effects of West Nile virus - Bird Flu
Intervet's Bird Flu Vaccine Receives EU License - Bird Flu
U.S. Preparedness to Respond to Avian Influenza a (H5N1) Strengthened by CDC/CSTE Partnership - Epidemic
Pulitzer Prize Winner Revisits Epicenter of Nation's Polio Epidemic - Flu Vaccines
Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1) - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
